An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 lowblasts

Khan, Naeem, Freeman, Sylvie D., Virgo, Paul, Couzens, Steve, Richardson, Peter, Thomas, Ian, Grech, Angela, Vyas, Paresh, Grimwade, David, Russell, Nigel H., Burnett, Alan K. and Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062 2015. An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 lowblasts. British Journal of Haematology 170 (1) , pp. 80-84. 10.1111/bjh.13398

Full text not available from this repository.

Abstract

Many older patients with acute myeloid leukaemia (AML) that receive standard intensive chemotherapy fail to achieve complete remission (CR). Upfront identification of patients unlikely to benefit from standard induction chemotherapy would be important for exploration of novel therapies. This study evaluated if a flow cytometric assay measuring pre-treatment CD34+ CD38low blast frequency could predict therapeutic-resistance in 736 AML patients entered into the UK National Cancer Research Institute AML16 trial. High peripheral blood CD34+ CD38low blast frequency (>7% of leucocytes), present in 18% of assessable patients, conferred significantly reduced CR rates (38% vs. 76%, P < 0·0001) and poor survival, and was independently prognostic for all endpoints of treatment resistance by multivariate analysis.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Uncontrolled Keywords:	acute myeloid leukaemia; older patients; flow cytometry; prognostic
Publisher:	Wiley-Blackwell
ISSN:	0007-1048
Date of Acceptance:	4 February 2015
Last Modified:	31 Oct 2022 10:22
URI:	https://orca.cardiff.ac.uk/id/eprint/84583

Citation Data

Cited 10 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item